Back to Search
Start Over
Personalized cancer vaccines: adjuvants are important, too.
- Source :
-
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2018 Dec; Vol. 67 (12), pp. 1911-1918. Date of Electronic Publication: 2018 Apr 11. - Publication Year :
- 2018
-
Abstract
- Therapeutic cancer vaccines have shown limited clinical efficacy so far. Nevertheless, in the meantime, our understanding of immune cell function and the interactions of immune cells with growing tumors has advanced considerably. We are now in a position to invest this knowledge into the design of more powerful vaccines and therapy combinations aimed at increasing immunogenicity and decreasing tumor-induced immunosuppression. This review focuses essentially on peptide-based human vaccines. We will discuss two aspects that are critical for increasing their intrinsic immunogenicity: the selection of the antigen(s) to be targeted, and the as yet unmet need for strong adjuvants.
- Subjects :
- Adjuvants, Immunologic
Animals
Antigens, Neoplasm immunology
Humans
Immunogenicity, Vaccine immunology
Immunotherapy methods
Neoadjuvant Therapy
Vaccines, Subunit immunology
Vaccines, Subunit therapeutic use
Cancer Vaccines immunology
Cancer Vaccines therapeutic use
Neoplasms immunology
Neoplasms therapy
Precision Medicine methods
Subjects
Details
- Language :
- English
- ISSN :
- 1432-0851
- Volume :
- 67
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Cancer immunology, immunotherapy : CII
- Publication Type :
- Academic Journal
- Accession number :
- 29644387
- Full Text :
- https://doi.org/10.1007/s00262-018-2158-4